<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Pharmacology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CA56942E-18DE-45C1-8F45-6C572E0F1D0A"><gtr:id>CA56942E-18DE-45C1-8F45-6C572E0F1D0A</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>Barrie</gtr:otherNames><gtr:surname>La Thangue</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000807"><gtr:id>1A4AC32C-8F23-4A4E-9EEF-7B2EE6BDF21B</gtr:id><gtr:title>The E2F pathway: new levels of control and regulation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000807</gtr:grantReference><gtr:abstractText>Cancer results from abnormal cell growth and division, and is frequently described as a disease of the cell cycle. The cell cycle refers to the process through which one cell grows and divides which, in normal healthy cells, is a tightly regulated process. The cell cycle is divided into four phases, where a major point of control exists as cells progress from the initial G1 phase into S phase, which is when cells begin to synthesise and copy their DNA in preparation for cell division. In mammalian cells, E2F is a control protein of central importance because it governs whether cells do or do not enter S phase. The activity of E2F is regulated by a number of key proteins that act as a ?braking? system, and includes the retinoblastoma tumour suppressor protein (pRb) which, by forming a protein complex with E2F, block E2F activity. Most importantly, in human tumour cells pRb is usually inactive, which means that the normally tightly regulated E2F activity is unleashed, providing a permanent signal that drives cells into unrestrained growth and division. The programme of study described here wants to dissect the role and regulation of different types of E2F activity, and assess the contribution to normal and tumour cell growth. Because of the abnormal control of E2F in cancer, this study is likely to identify new therapeutic opportunities for preventing the growth of tumour cells.</gtr:abstractText><gtr:technicalSummary>E2F transcription factors are widely viewed as essential regulators of cell cycle progression through their ability to co-ordinate and integrate cell cycle events with the transcription machinery. E2F activity has been connected with a variety of cell fates, including differentiation, apoptosis, senescence and autophagy, and is attributed with a major role in driving tumourigenesis. Since the original definition of E2F DNA binding complexes in mammalian cells, it has become apparent that E2F is a family of transcription factors with diverse physiological roles that has been highly conserved throughout evolution. It remains a major challenge to decipher the biology of individual E2F family members, and understand the physiological cues that drive the diverse outcomes that have been assigned to E2F activity. Knowledge about the regulatory events that influence E2F activity is therefore of considerable importance in understanding the complexity of cell cycle control and abnormalities that contribute to cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2016-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1815455</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>Structural elucidation of epigenetic regulators</gtr:description><gtr:id>7093F2B5-67D2-4F08-8C08-BC37BC8C581C</gtr:id><gtr:impact>Publication of the following papers:
Carr SM, Munro S, Zalmas LP, Fedorov O, Johansson C, Krojer T, Sagum CA, Bedford MT, Oppermann U, La Thangue NB. (2014) Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor. Proc Natl Acad Sci U S A. Jul 21. pii: 201403737. [Epub ahead of print]

Munro, S., Oppermann, U. and La Thangue, N.B. (2013) Pleiotropic effect of somatic mutations in the E2F subunit DP-1 gene in human cancer. Oncogene, doi: 10.1038/onc.2013.316. Oncogene 33 (27); 3594-603

Carr SM, Munro S, Kessler B, Oppermann U, La Thangue NB (2011) Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO Journal 30: 317-327</gtr:impact><gtr:outcomeId>54635f399bfab4.09684884-1</gtr:outcomeId><gtr:partnerContribution>Structural biology</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical Pathology</gtr:description><gtr:id>BA0E1A59-7A21-4E49-831E-EF7614D16E79</gtr:id><gtr:impact>Publication of the following article:

Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards R. and La Thangue, N. B. (2009) Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15 57-66.</gtr:impact><gtr:outcomeId>54636093671d40.34542133-1</gtr:outcomeId><gtr:partnerContribution>Pathology expertise</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Proteomics</gtr:description><gtr:id>71BBB731-39EA-4DD7-A723-62CC1ABE6AE7</gtr:id><gtr:impact>Publication of the following papers:
Maniam, S., Coutts, A.S., Stratford, M.R., McGouran, J., Kessler, B., and La Thangue, N.B. (2014) p53 regulates oxidative phosphorylation through ATP synthase, Cell Death and Differentiation: in press
Jansson, M., Durant, S.T., Cho, E.C., Sheahan, S., Edelmann, M., Kessler, B., and La Thangue, N.B. (2008). Arginine methylation regulates the p53 response. Nature Cell Biology 10, 1431-1439.</gtr:impact><gtr:outcomeId>54636005a9e052.10715239-1</gtr:outcomeId><gtr:partnerContribution>Mass spectrometry</gtr:partnerContribution><gtr:piContribution>Cancer Biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical trials</gtr:description><gtr:id>87CE8D35-6484-48F1-8B52-323A3DFD26C7</gtr:id><gtr:impact>Exemplification of a new epigenetic regulator in human cancer patients</gtr:impact><gtr:outcomeId>56d71ae183eed8.59065425-1</gtr:outcomeId><gtr:partnerContribution>clinical studies</gtr:partnerContribution><gtr:piContribution>Drug design and development, biomarker and companion diagnostic characterisation</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B509FEBF-A3F7-41DB-B501-2A0F2EE816AF</gtr:id><gtr:impact>Open days, seminars to the lay public, general reviews in lay journals

More awareness</gtr:impact><gtr:outcomeId>E87BE302BAE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A83AFA86-E76F-4EED-B9DC-F3512CD85987</gtr:id><gtr:impact>Seminar to public

wider understanding</gtr:impact><gtr:outcomeId>EDF2865FA6D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Journal</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DCCD57EA-4A18-429A-ADA4-F9F2623D7E81</gtr:id><gtr:impact>contribute to journal

distribution to public</gtr:impact><gtr:outcomeId>D67358CF6D7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The E2F pathway of growth control</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8EA61F19-2ACC-405C-8A3D-7338994B22FF</gtr:id><gtr:outcomeId>69CF6A3F9A50</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Researchers became specalized in Cancer Research and non-researchers became aware of developments in Cancer Research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>26C043B0-B526-4893-A4EE-575DE45EB1BF</gtr:id><gtr:outcomeId>C2953DFAEFF</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Celleron Therapeutics</gtr:companyName><gtr:description>Therapeutic Company; http://cellerontherapeutics.com/</gtr:description><gtr:id>20446A4A-BC95-439E-9FFC-6A5D6CCB1C48</gtr:id><gtr:impact>Drug discovery</gtr:impact><gtr:outcomeId>D0F1F338EBC</gtr:outcomeId><gtr:url>http://cellerontherapeutics.com/</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Profilix</gtr:companyName><gtr:description>Therapeutic; merged with TopoTarget in 2002</gtr:description><gtr:id>19AC792E-0FBD-41EC-8107-8CFE37C96EEF</gtr:id><gtr:impact>Drug development</gtr:impact><gtr:outcomeId>96C141F9EFB</gtr:outcomeId></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Oxford Cancer Biomarkers</gtr:companyName><gtr:description>http://oxfordcancerbiomarkers.com/index2.php</gtr:description><gtr:id>F96F1F4C-78E1-4BA2-9C47-3F14B8A352E9</gtr:id><gtr:impact>0</gtr:impact><gtr:outcomeId>qMb3TpLLATU</gtr:outcomeId><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>D53A3CE6-62BB-4563-9825-41436F36AFE1</gtr:id><gtr:title>Citrullination-acetylation interplay guides E2F-1 activity during the inflammatory response.</gtr:title><gtr:parentPublicationTitle>Science advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/645d826a2aac8cfef39f45eabd8af26e"><gtr:id>645d826a2aac8cfef39f45eabd8af26e</gtr:id><gtr:otherNames>Ghari F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2375-2548</gtr:issn><gtr:outcomeId>58b83be60c7609.57655960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E57DCFAE-7E54-4F4E-B00E-E974DE9E6ABE</gtr:id><gtr:title>Pleiotropic effect of somatic mutations in the E2F subunit DP-1 gene in human cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0488141f55304a0a3356e25515e85c3"><gtr:id>e0488141f55304a0a3356e25515e85c3</gtr:id><gtr:otherNames>Munro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_53cd4afd4afe44df1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C3D6DA4-25D7-46A5-9C7B-536107CBE885</gtr:id><gtr:title>eLS</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:outcomeId>5462293e522d19.61821034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBB4CF41-F712-4E30-9A82-631F70FC1235</gtr:id><gtr:title>Lysine methylation and the regulation of p53.</gtr:title><gtr:parentPublicationTitle>Essays in biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0071-1365</gtr:issn><gtr:outcomeId>pm_16448_28_22708565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BCD4CA3-978B-42EC-999D-6E6564F44793</gtr:id><gtr:title>Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.</gtr:title><gtr:parentPublicationTitle>Cell chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06cb31360610c1669579280511aa088d"><gtr:id>06cb31360610c1669579280511aa088d</gtr:id><gtr:otherNames>Tumber A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2451-9448</gtr:issn><gtr:outcomeId>5a997c2366cbb4.02181451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C75B1F9E-139C-4E83-864E-FA2723CDF2C1</gtr:id><gtr:title>A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ade538f7492abc96c06f942de91652f"><gtr:id>4ade538f7492abc96c06f942de91652f</gtr:id><gtr:otherNames>New M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>pm_16448_28_23703321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E91690C9-FF3E-474B-90E6-3E7499FFA1EF</gtr:id><gtr:title>JMY protein, a regulator of P53 and cytoplasmic actin filaments, is expressed in normal and neoplastic tissues.</gtr:title><gtr:parentPublicationTitle>Virchows Archiv : an international journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b52cb53a525b4d4303665c68c7922f54"><gtr:id>b52cb53a525b4d4303665c68c7922f54</gtr:id><gtr:otherNames>Adighibe O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0945-6317</gtr:issn><gtr:outcomeId>56d71429b92903.21768515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF34F025-BFBE-47E0-808E-31CB795152FC</gtr:id><gtr:title>Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1a.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_53cd4b0d4b02cbc67</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B1E86DE-E4BE-4D34-8B04-2C69141D0148</gtr:id><gtr:title>Encyclopedia of Molecular Cell Biology and Molecular Medicine</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0816806c50bd8a065dc349870ebb4a70"><gtr:id>0816806c50bd8a065dc349870ebb4a70</gtr:id><gtr:otherNames>La Thangue N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:isbn>9783527600908</gtr:isbn><gtr:outcomeId>iznyF4bpT4L</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D956D48-518A-4B12-96FB-14A6B24B0A6B</gtr:id><gtr:title>Clinical Exemplification of HDAC Inhibitors: From Bench to Clinic, and Back Again</gtr:title><gtr:parentPublicationTitle>The Journal of OncoPathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54622ba08f1dd2.23017102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1430EAB1-F0B7-49C9-813F-3D2BE018957B</gtr:id><gtr:title>Oxford Textbook of Oncology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>MLALM3Q6PvP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17434F49-F653-4913-B671-7B244F368C8E</gtr:id><gtr:title>Tudor-domain protein PHF20L1 reads lysine methylated retinoblastoma tumour suppressor protein.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>5a997c22cc8ef6.69044178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE423704-141D-43B7-8EB0-E698C4B2F118</gtr:id><gtr:title>Linking H1 with chromatin and growth control.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0488141f55304a0a3356e25515e85c3"><gtr:id>e0488141f55304a0a3356e25515e85c3</gtr:id><gtr:otherNames>Munro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2372-3556</gtr:issn><gtr:outcomeId>5a997c230c6555.37058353</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3DB4CC9-830A-4E72-9B75-159E21609FA0</gtr:id><gtr:title>Oncology biomarkers in clinical practice - a new horizon</gtr:title><gtr:parentPublicationTitle>Drug Target Review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c95c284bc6b418511194748af9d10d95"><gtr:id>c95c284bc6b418511194748af9d10d95</gtr:id><gtr:otherNames>Sheikh, S.,</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5444dab48e9f22.02331904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8320F1B8-E07B-42F1-9064-DD369AE23789</gtr:id><gtr:title>How to get better value cancer care</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8331fb33eef4b73238de0ad4862f84f4"><gtr:id>8331fb33eef4b73238de0ad4862f84f4</gtr:id><gtr:otherNames>La Thangue NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>iQenjPpLbZK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D2D6662-5D3C-442E-B689-53E33F849FED</gtr:id><gtr:title>The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structure.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad778125cc3dc9a3b6408f2e444e67f9"><gtr:id>ad778125cc3dc9a3b6408f2e444e67f9</gtr:id><gtr:otherNames>Adams CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_16448_28_22362889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF66F29E-DE67-4D8E-A353-96CAF82BE08B</gtr:id><gtr:title>Predictive biomarkers: a paradigm shift towards personalized cancer medicine.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8331fb33eef4b73238de0ad4862f84f4"><gtr:id>8331fb33eef4b73238de0ad4862f84f4</gtr:id><gtr:otherNames>La Thangue NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>aQiwmLKgeT4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>258B4F4C-F5B8-4CEB-97C5-F667A82B23DB</gtr:id><gtr:title>Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 activity through ATP synthase.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b58dcf49b89d2c6b1a1ed379a31a048b"><gtr:id>b58dcf49b89d2c6b1a1ed379a31a048b</gtr:id><gtr:otherNames>Maniam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>543e3ab466b5c5.00542304</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FCB3696-8417-4FB4-9B45-7D3E3541530C</gtr:id><gtr:title>NEDDylation regulates E2F-1-dependent transcription.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71d5d197f0bb3f01afa1ea32148698bb"><gtr:id>71d5d197f0bb3f01afa1ea32148698bb</gtr:id><gtr:otherNames>Loftus SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>pm_16448_28_22836579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F58CF80-18ED-40DE-A311-A991B57D2EA4</gtr:id><gtr:title>HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.</gtr:title><gtr:parentPublicationTitle>Immunology and cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc088ca797e035b292f2f3103320da6b"><gtr:id>cc088ca797e035b292f2f3103320da6b</gtr:id><gtr:otherNames>Khan O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0818-9641</gtr:issn><gtr:outcomeId>pm_16448_28_22124371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F207EAEB-7FBB-4E2E-B379-67D1082C4C29</gtr:id><gtr:title>SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76532b54344c18c0287d1f9e3a50d7c9"><gtr:id>76532b54344c18c0287d1f9e3a50d7c9</gtr:id><gtr:otherNames>Pfister SX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>543e3cae5548d6.82776058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AAD43D2-23A8-41B8-BE57-CB6D8DC3DA2F</gtr:id><gtr:title>Actin nucleation by WH2 domains at the autophagosome.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5675e9899a657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9398B0D2-B019-4421-9303-5079B9699B64</gtr:id><gtr:title>CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation.</gtr:title><gtr:parentPublicationTitle>Cell chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2451-9448</gtr:issn><gtr:outcomeId>58b83be51ec7b9.31105310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F577244-3A34-47DB-BD98-BAC02ADAD196</gtr:id><gtr:title>HDAC inhibitor-based therapies: can we interpret the code?</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ade538f7492abc96c06f942de91652f"><gtr:id>4ade538f7492abc96c06f942de91652f</gtr:id><gtr:otherNames>New M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>54631e5573d445.16774716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBADC903-8BED-4982-8DBA-3F8557FFBD20</gtr:id><gtr:title>Diversity within the pRb pathway: is there a code of conduct?</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0488141f55304a0a3356e25515e85c3"><gtr:id>e0488141f55304a0a3356e25515e85c3</gtr:id><gtr:otherNames>Munro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_16448_28_22249267</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61171092-DA2C-4012-B3A2-D99294C93384</gtr:id><gtr:title>Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88d2cb4b08cd1931093e1e6e19a74d41"><gtr:id>88d2cb4b08cd1931093e1e6e19a74d41</gtr:id><gtr:otherNames>Kawalkowska J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b83be5774f27.54448865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8220E254-6A94-495C-B753-A3DA72D13E38</gtr:id><gtr:title>Structural analysis of human KDM5B guides histone demethylase inhibitor development.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bee931d752a276728f5b7a8b416a9c9"><gtr:id>7bee931d752a276728f5b7a8b416a9c9</gtr:id><gtr:otherNames>Johansson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>58b83d3ec99c41.88634444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15DA9253-60DC-4180-94F6-D6459D670F83</gtr:id><gtr:title>Post-translational control of transcription factors: methylation ranks highly.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>58b83be6552d52.55080839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95AF94C6-69AD-4384-89D6-CC7563005FE7</gtr:id><gtr:title>Cell cycle control by a methylation-phosphorylation switch.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>W6n8fvsSqXh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EA55C0E-5F1C-4C0D-A1DF-438099CAF02E</gtr:id><gtr:title>HDAC Inhibitors.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>58b83be5bf76d7.87321538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0544743-398C-49D9-80A4-6A8833B32996</gtr:id><gtr:title>Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8eb7ad51086c67586929108c4211fa74"><gtr:id>8eb7ad51086c67586929108c4211fa74</gtr:id><gtr:otherNames>Picaud S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>56d714295df979.18846828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39CF27E7-EC50-4699-91BF-CEAF54F69596</gtr:id><gtr:title>Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a340fbb42265c9ec6bc733e0a04c590"><gtr:id>2a340fbb42265c9ec6bc733e0a04c590</gtr:id><gtr:otherNames>Zheng S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>pm_16448_28_24076217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9698C7EB-7753-4432-A720-0913D9081705</gtr:id><gtr:title>Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76532b54344c18c0287d1f9e3a50d7c9"><gtr:id>76532b54344c18c0287d1f9e3a50d7c9</gtr:id><gtr:otherNames>Pfister SX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>56d712ba468e44.03710300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7411B8C-3119-4B51-9AAB-106997026D21</gtr:id><gtr:title>Actin nucleators in the nucleus: an emerging theme.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8680c526c850249788ecad73d36a8e3b"><gtr:id>8680c526c850249788ecad73d36a8e3b</gtr:id><gtr:otherNames>Weston L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>54631f94710553.35389801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>832E8468-EB05-4D4D-9041-AFF03E51B51C</gtr:id><gtr:title>TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ade538f7492abc96c06f942de91652f"><gtr:id>4ade538f7492abc96c06f942de91652f</gtr:id><gtr:otherNames>New M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>58b83be4c34131.82705791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD7E3299-5E8C-4D3C-A2F5-21D37FEBC4A7</gtr:id><gtr:title>T-ARG-eting E2F-1 growth control.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a83599a96ae9f33f8304a803366eb9be"><gtr:id>a83599a96ae9f33f8304a803366eb9be</gtr:id><gtr:otherNames>Moehlenbrink J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_16448_28_22871730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D71BB89E-82D1-4EA0-BC76-1AB1F27A2107</gtr:id><gtr:title>Linker Histone H1.2 Directs Genome-wide Chromatin Association of the Retinoblastoma Tumor Suppressor Protein and Facilitates Its Function.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0488141f55304a0a3356e25515e85c3"><gtr:id>e0488141f55304a0a3356e25515e85c3</gtr:id><gtr:otherNames>Munro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a997c23331e73.64933161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E41A9D3-3C2D-4618-B502-244DDD688EC8</gtr:id><gtr:title>Regulation of actin nucleation and autophagosome formation.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f311efa23aeae0cd1c328c0cf37ff446"><gtr:id>f311efa23aeae0cd1c328c0cf37ff446</gtr:id><gtr:otherNames>Coutts AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn><gtr:outcomeId>585d32498ac2e9.90314914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>375A875D-6D46-4EAA-9E39-8D2A3D44F360</gtr:id><gtr:title>Selective inhibition of BET bromodomains.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82d26cad18a3b34bdf077e0d3b841513"><gtr:id>82d26cad18a3b34bdf077e0d3b841513</gtr:id><gtr:otherNames>Filippakopoulos P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>545ccc35ceb9b9.75819673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CF53CFB-0796-4917-B732-D6EC0AF2B59A</gtr:id><gtr:title>E2F-1 regulation by an unusual DNA damage-responsive DP partner subunit.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52edaa3d5159d0557a59988fc480ba6f"><gtr:id>52edaa3d5159d0557a59988fc480ba6f</gtr:id><gtr:otherNames>Ingram L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>doi_53cd4ad4af9ec88c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8CD0E7B-7791-4A66-9EDD-2F3BFD2490AD</gtr:id><gtr:title>Deacetylation of chromatin and gene expression regulation: a new target for epigenetic therapy.</gtr:title><gtr:parentPublicationTitle>Critical reviews in oncogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c23f382501564b9bd4884d5a95f2ee"><gtr:id>13c23f382501564b9bd4884d5a95f2ee</gtr:id><gtr:otherNames>Olzscha H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0893-9675</gtr:issn><gtr:outcomeId>56d714298d6149.09792373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81498B45-1336-43BF-88AE-8C44D2ECA44E</gtr:id><gtr:title>E2F-7 couples DNA damage-dependent transcription with the DNA repair process.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c28a22b36d3a50c513cbeeb2da12fd5"><gtr:id>9c28a22b36d3a50c513cbeeb2da12fd5</gtr:id><gtr:otherNames>Zalmas LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_16448_28_23974101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC668116-5588-4052-A99C-1D1D0FB27BCD</gtr:id><gtr:title>Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>RTXWfbVuPnL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA602D59-A4E9-4E2D-ADFC-39C24D2642C5</gtr:id><gtr:title>To live or let die - complexity within the E2F1 pathway.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4b1d53b64045b4809079e1aabcead13"><gtr:id>e4b1d53b64045b4809079e1aabcead13</gtr:id><gtr:otherNames>Poppy Roworth A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2372-3556</gtr:issn><gtr:outcomeId>5444d8985d6ce0.28247308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CADA38DB-8810-4E6E-A4B0-B1220890E833</gtr:id><gtr:title>Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e154330a717af1010273fbe531c4567"><gtr:id>8e154330a717af1010273fbe531c4567</gtr:id><gtr:otherNames>Carr SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>543e3eb92b0d39.73250450</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000807</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>